验证简化的国际预后评分（IPS-3）在晚期经典霍奇金淋巴瘤患者中的应用。
Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma.
机构信息
Department of Medical Oncology, British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, Canada.
Department of Math, Statistics, and Computer Science, St. Francis Xavier University, Antigonish, NS, Canada.
出版信息
Br J Haematol. 2020 Apr;189(1):122-127. doi: 10.1111/bjh.16293. Epub 2019 Dec 10.
A novel prognostic score (IPS-3), comprised of only three of the seven IPS-7 indicators (age ≥45, stage IV, haemoglobin <105 g/l), was recently proposed as a simplified model for advanced-stage classic Hodgkin lymphoma (cHL). We aimed to validate this model in advanced-stage cHL patients treated with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in British Columbia. The estimated five-year freedom from progression (FFP) for scores of 0, 1, 2 and 3 were very similar to the original report at 84%, 76%, 72% and 68% respectively. The IPS-3 score is highly reproducible in this independent dataset and its simplicity makes it appealing for everyday clinical practice.
最近提出了一种新的预后评分（IPS-3），该评分仅由 IPS-7 指标中的三个组成（年龄≥45 岁、IV 期、血红蛋白<105g/l），作为晚期经典霍奇金淋巴瘤（cHL）的简化模型。我们旨在在不列颠哥伦比亚省接受多柔比星、博来霉素、长春碱、达卡巴嗪（ABVD）治疗的晚期 cHL 患者中验证该模型。评分 0、1、2 和 3 的估计五年无进展生存期（FFP）分别与原始报告非常相似，分别为 84%、76%、72%和 68%。IPS-3 评分在这个独立数据集具有高度可重复性，其简单性使其在日常临床实践中具有吸引力。
Zotero 插件